Voltar
Artigo Acesso aberto Produção Nacional Revisado por pares
BIBTEX RIS

Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial

2022; Associação de Psiquiatria do Rio Grande do Sul; Linguagem: Inglês

10.47626/2237-6089-2021-0396

ISSN

2238-0019

Autores

Estácio Amaro da Silva Júnior, Wandersonia Moreira Brito Medeiros, João Paulo Mendes dos Santos, João Marçal Medeiros de Sousa, Filipe Barbosa da Costa, Katiúscia Moreira Pontes, Thaís Cavalcanti Borges, Carlos Espínola Neto Segundo, Ana Hermínia Andrade e Silva, Eliane Lima Guerra Nunes, Nelson Torro Alves, Marine Diniz da Rosa, Katy Lísias Gondim Dias de Albuquerque,

Tópico(s)

Child Nutrition and Feeding Issues

Resumo

Autism spectrum disorder (ASD) is characterized by persistent deficits in social communication and social interaction and by restricted and repetitive patterns of behavior. Some studies have shown that substances derived from Cannabis sativa improve the quality of life of children with ASD without causing serious adverse effects, thus providing an alternative therapeutic option. The objective of this study was to evaluate the efficacy and safety of a cannabis extract rich in cannabidiol (CBD) in children with ASD.

Referência(s)